House Energy and Commerce Committee subpanel chairs
Democratic Caucus of the House Energy and Commerce Committee announces subcommittee assignments for the 111 Congress, following the takeover of the chairmanship of the full committee by Rep. Henry Waxman, D-Calif., from Rep. John Dingell, D-Mich., in November ("1The Gray Sheet" Nov. 24, 2008, p. 5). Rep. Frank Pallone, D-N.J., will retain his chairmanship of the Health Subcommittee, which handles most FDA-related legislation, and Bart Stupak, D-Mich., who has been trying to persuade the incoming Obama administration to "clean house" at FDA, will retain his chairmanship of the Oversight and Investigations subpanel. Stupak sent a letter in December to the Obama transition team, asking, among other things, that no current senior FDA employee be put in charge of the agency, even on an interim basis ("2The Gray Sheet" Dec. 15, 2008, p. 23)
More from Archive
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
More from Medtech Insight
HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.
The US FDA needs to know who wants a seat at the MDUFA negotiations table before discussions can begin. The agency is asking stakeholders to let it know if they plan to participate in the periodic consultation meetings before July 28.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 50 documents have been posted on the tracker since its last update.